Expanding Patient Reach And Pipeline Development Will Unlock Potential
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
26 May 25
Updated
17 Jul 25
AnalystConsensusTarget's Fair Value
US$130.60
0.9% undervalued intrinsic discount17 Jul
US$129.46
1Y
14.1%7D
0.1%